Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 19% over the past year, with earnings forecasted to grow by 18% annually. In this environment, identifying high growth tech stocks involves looking for companies that not only show strong potential for revenue growth but also demonstrate resilience and adaptability in fluctuating market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.41%	21.98%	★★★★★★
Fabrinet	21.38%	23.34%	★★★★★★
Krystal Biotech	29.15%	36.59%	★★★★★★
Palantir Technologies	30.88%	31.93%	★★★★★★
Reddit	21.88%	25.35%	★★★★★★
Sandisk	39.77%	36.56%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
KVH Industries	28.67%	146.09%	★★★★★☆
Circle Internet Group	21.50%	49.04%	★★★★★☆
Duos Technologies Group	61.81%	48.23%	★★★★★☆

Below we spotlight a couple of our favorites from our exclusive screener.

Five9 (FIVN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Five9, Inc. offers intelligent cloud software solutions for contact centers globally, with a market capitalization of approximately $1.49 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, with reported earnings of $1.17 billion.

With an annualized revenue growth of 8% and earnings expected to surge by 25.9% per year, Five9 is positioning itself as a formidable contender in the tech sector, particularly with its recent advancements in AI-driven customer service solutions. The company's R&D focus is evident from its latest product launch—Voice AI Agents—which are set to revolutionize enterprise customer interactions through advanced AI that not only responds but actively resolves queries by integrating deeply with organizational workflows. This innovation underscores Five9's commitment to maintaining a competitive edge in a market increasingly reliant on sophisticated AI solutions for enhancing customer experience. Moreover, the strategic executive changes and $70.934 million shelf registration signal robust organizational adjustments aimed at sustaining growth and market responsiveness.

Vericel (VCEL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and distributing cellular therapies and specialty biologic products for the sports medicine and severe burn care markets in North America, with a market capitalization of approximately $2.13 billion.

Operations: Vericel focuses on cellular therapies and specialty biologics, generating revenue of $292.09 million from its biotechnology segment.

Vericel stands out with a remarkable 620.7% earnings growth over the past year, significantly outpacing its industry's average. This surge is projected to continue, with earnings expected to grow at an annual rate of 33.1%, eclipsing the US market forecast of 18.5%. Contributing to this robust financial performance is a substantial contract awarded by BARDA valued at up to $197 million for NexoBrid, enhancing Vericel's strategic position in biotech and emergency medical treatments. The company also raised its 2026 revenue outlook from $316 million to as much as $336 million following strong Q1 results, signaling confidence in sustained growth amidst dynamic market conditions.

Krystal Biotech (KRYS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines to address diseases with high unmet medical needs in the United States, with a market cap of $10.25 billion.

Operations: Krystal Biotech generates revenue primarily from its activities in discovering, developing, manufacturing, and commercializing genetic medicines, totaling $417.30 million. The company operates within the biotechnology sector to address diseases with significant unmet medical needs in the U.S.

Krystal Biotech's recent strides in the biotech sector underscore its growth trajectory, with a notable 29.1% annual revenue increase and a robust 36.6% earnings growth forecast surpassing the US market average of 18.4%. The company's significant R&D commitment, reflected in an 81.5% earnings surge over the past year, fuels innovations like VYJUVEK—recently approved in the UK for treating dystrophic epidermolysis bullosa (DEB). This approval not only opens new markets but also extends Krystal’s influence across regulatory environments, enhancing its competitive edge while promising sustained advancements through gene therapy solutions.

Make It Happen

• Explore the 65 names from our US High Growth Tech and AI Stocks screener here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.